{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multiple-myeloma/management/end-stage-multiple-myeloma/","result":{"pageContext":{"chapter":{"id":"1544f647-8ce2-51e4-adee-9cb61fc46ae1","slug":"end-stage-multiple-myeloma","fullItemName":"Scenario: End-stage multiple myeloma","depth":2,"htmlHeader":"<!-- begin field 960057c8-2730-451c-a215-30ce4f4b81f5 --><h2>Scenario: End-stage multiple myeloma</h2><!-- end field 960057c8-2730-451c-a215-30ce4f4b81f5 -->","summary":"Covers when to suspect end-stage multiple myeloma and the management of a person with end-stage multiple myeloma.","htmlStringContent":"<!-- begin item af434fd5-512f-48af-91ee-4f7c0f2122ba --><!-- begin field 21553abc-5b49-4493-abeb-acd900adf523 --><p>From age 18 years onwards.</p><!-- end field 21553abc-5b49-4493-abeb-acd900adf523 --><!-- end item af434fd5-512f-48af-91ee-4f7c0f2122ba -->","topic":{"id":"a3257bde-777f-5b48-80cd-28a6de5401b7","topicId":"d449062b-fe98-40a2-bc4d-741f0b91c31d","topicName":"Multiple myeloma","slug":"multiple-myeloma","lastRevised":"Last revised in January 2021","chapters":[{"id":"001bce70-f61f-5905-b9a0-76e49dc2928b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a4e4ac31-e5c3-5d0d-ba8e-e28d748b38a8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d731856b-56b9-5d81-9db1-6e0380152383","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"288251ee-9e56-550b-bb07-75c191dd88bb","slug":"changes","fullItemName":"Changes"},{"id":"972750f6-1493-51ac-bb67-61a883caef31","slug":"update","fullItemName":"Update"}]},{"id":"9ee3d2ca-5de2-5a81-be8d-5389cb6b96fb","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"02fc2e8c-0154-52e2-81b7-13f9f7ae4157","slug":"goals","fullItemName":"Goals"},{"id":"297bf476-1f3c-5477-859b-fc44c3d58cdd","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca441620-7e21-5b08-9340-cca6210d21e9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"23d46a0d-5d23-5d38-a2d7-817babead45a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f4644ec-a108-52f6-874b-8644bd8da047","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c6fdac6a-e178-59a4-bcb7-a22337d627a4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c45f4611-e831-51b1-ae27-0421b247f510","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7e70c907-9e94-5f79-b9bb-ba6799a19ccd","slug":"definition","fullItemName":"Definition"},{"id":"64fa3b9a-e0f1-5f2c-aa6b-99ca7f657bb9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"222268d1-82ef-5947-9a94-81c9475bd101","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"f2cd915a-2200-5a59-9f4b-e92d4e9721d6","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b84e32aa-3d7d-5e4b-a3d8-9c8cc506b4a9","slug":"complications","fullItemName":"Complications"}]},{"id":"cd2396e2-8290-5f66-ad0f-871bfebc83dd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d1d186e7-f167-55b0-a9ba-20bc6df07ce9","slug":"when-should-i-suspect-multiple-myeloma","fullItemName":"When should I suspect multiple myeloma?"},{"id":"8116b468-694e-5fa4-aa60-09f23bc088e0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"46717c89-6886-52dc-8e80-d8fb592c32b2","fullItemName":"Management","slug":"management","subChapters":[{"id":"da1a6baa-3eff-5249-bb76-6d086063c369","slug":"suspected-multiple-myeloma","fullItemName":"Scenario: Suspected multiple myeloma"},{"id":"c51edfd3-b143-5dfe-b734-2f46b572a5de","slug":"confirmed-multiple-myeloma","fullItemName":"Scenario: Confirmed multiple myeloma"},{"id":"1544f647-8ce2-51e4-adee-9cb61fc46ae1","slug":"end-stage-multiple-myeloma","fullItemName":"Scenario: End-stage multiple myeloma"}]},{"id":"375c8b98-56b6-5c85-a182-36856a3db2ca","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b088260f-8cf4-5102-b99d-ab78d3ac71d3","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"ddabb890-df48-5057-a56f-32666fa74e9a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"9764188e-1795-5b4f-8cdf-b70befc3fe0d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"aef9e65b-4f13-546f-adbc-19654498aa31","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"79a1401a-ca39-5eff-ab8b-482281e9741f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b84ca8eb-2866-56cb-b7a1-ecb59575fddc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"592f1670-1381-587b-baec-8618a8caf851","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e6e2cada-c7c4-5f01-bf87-9cecee0c53f0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6b485c3d-36d7-556a-993b-3311a38b7bf6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"46717c89-6886-52dc-8e80-d8fb592c32b2","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"ddf30e4d-d6cb-542e-9ec3-122b471238bd","slug":"when-should-i-suspect-end-stage-multiple-myeloma","fullItemName":"When should I suspect end-stage multiple myeloma?","depth":3,"htmlHeader":"<!-- begin field e8e2b9e6-41c6-4af5-a791-d64e833f4234 --><h3>When should I suspect end-stage multiple myeloma?</h3><!-- end field e8e2b9e6-41c6-4af5-a791-d64e833f4234 -->","summary":null,"htmlStringContent":"<!-- begin item ec5d6587-bddb-4411-9c3f-1b5d789dee93 --><!-- begin field 72024b5c-f17a-4b9d-9da4-6af9f298f5d6 --><ul><li><strong>Disease course in multiple myeloma can be difficult to predict </strong>— the person may go through multiple lines of treatment and experience periods of relapse and remission.<ul><li>After each line of treatment, the chance of remission decreases and potential for adverse effects increases — decisions on when to stop active treatment can be difficult.</li><li>Movement from stable to late-stage disease can occur rapidly and the person may suddenly deteriorate — death may occur due to multiple myeloma itself or treatment-related complications.</li></ul></li><li><strong>Suspect end-stage multiple myeloma when symptoms become increasingly refractory to treatment.</strong> A range of issues may develop, including:<ul><li>Bone pain.</li><li>Renal failure.</li><li>Bone marrow failure.</li><li>Infection — infection is a common cause of death in people with multiple myeloma.</li><li>Increasing fatigue.</li><li>Anorexia and weight loss.</li><li>Changes in communication, deteriorating mobility or performance status, or social withdrawal.</li></ul></li><li>For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/\">Palliative care – general issues</a>.</li></ul><!-- end field 72024b5c-f17a-4b9d-9da4-6af9f298f5d6 --><!-- end item ec5d6587-bddb-4411-9c3f-1b5d789dee93 -->","subChapters":[{"id":"c60dfff9-0a28-507f-8d5c-a3faa2749a9a","slug":"basis-for-recommendation-e74","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1261f2c0-0e0a-49d4-a2a0-d1f9abb090e1 --><h4>Basis for recommendation</h4><!-- end field 1261f2c0-0e0a-49d4-a2a0-d1f9abb090e1 -->","summary":null,"htmlStringContent":"<!-- begin item e749fc96-26a3-402c-9447-09a99133f243 --><!-- begin field 2be328fc-252e-4879-afbf-2d831d64e33d --><p>The information on end-stage multiple myeloma is based on expert opinion in the British Committee for Standards in Haematology (BCSH) guideline <em>Supportive care in multiple myeloma</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Snowden, 2011</a>], the National Institute for Health and Care Excellence (NICE) guideline <em>Care of dying adults in the last days of life</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">NICE, 2015b</a>], review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Ramsenthaler, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Bird, 2019</a>], and the expert opinion of an external reviewer of this CKS topic.</p><!-- end field 2be328fc-252e-4879-afbf-2d831d64e33d --><!-- end item e749fc96-26a3-402c-9447-09a99133f243 -->","subChapters":[]}]},{"id":"7dbc69b1-6370-529d-bd8c-040134d5a031","slug":"how-should-i-manage-a-person-with-end-stage-multiple-myeloma","fullItemName":"How should I manage a person with end-stage multiple myeloma?","depth":3,"htmlHeader":"<!-- begin field 0a8154ab-5670-45b3-9ff3-116fdae473d7 --><h3>How should I manage a person with end-stage multiple myeloma?</h3><!-- end field 0a8154ab-5670-45b3-9ff3-116fdae473d7 -->","summary":null,"htmlStringContent":"<!-- begin item 30f6b3e0-ae51-42cc-8dd5-ab213e57b496 --><!-- begin field b10f31f3-3aa2-4804-92c9-194a66f0473f --><ul><li><strong>For people with end-stage multiple myeloma:</strong><ul><li>Ensure care is coordinated with the rest of the multidisciplinary team, including community district nurses, the palliative care team, physiotherapists, occupational therapists, speech and language therapists (SALTs), and adult social care as appropriate.</li><li>Early referral to the palliative care team improves end-of-life care and reduces emergency admissions.</li></ul></li><li><strong>Offer discussion with the person and their family/carers of end-of-life issues such as:</strong><ul><li>The disease process.</li><li>Treatments, including explanations of short-term crisis treatments.</li><li>What dying might be like and how symptoms might be alleviated.</li></ul></li><li><strong>Ensure the person has an advance care plan (if they wish) and discuss any advance decisions.</strong><ul><li>For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/management/communication/#important-communication-issues\">Important communication issues</a> in the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/\">Palliative care – general issues</a>.</li><li>Opportunities to review advance care plans can arise when there is a clinical event or deterioration, or when there is a change in social circumstances, such as a move into a care home.</li></ul></li><li><strong>Optimize the treatment of symptoms in conjunction with the person’s multiple myeloma team and palliative care services:</strong><ul><li>For general information on end-of-life care, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-general-issues/\">Palliative care - general issues</a>.</li><li>For information on treatment of:<ul><li>Breathlessness, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-dyspnoea/\">Palliative care - dyspnoea</a>.</li><li>Secretions, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-care-secretions/\">Palliative care - secretions</a>.</li><li>Pain, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/palliative-cancer-care-pain/\">Palliative cancer care - pain</a>.</li><li>Insomnia, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/insomnia/\">Insomnia</a>.</li><li>Depression, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>.</li><li>Anxiety, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>.</li></ul></li><li>Be aware that renal function often deteriorates in end-stage multiple myeloma and that drug doses (such as opiates) may require adjustment.</li><li>Consider the need for admission to a hospice (for example, if symptoms are not controlled, or if this is the preferred place of death).</li></ul></li></ul><!-- end field b10f31f3-3aa2-4804-92c9-194a66f0473f --><!-- end item 30f6b3e0-ae51-42cc-8dd5-ab213e57b496 -->","subChapters":[{"id":"5e2bd109-1442-55d7-884f-2428fcc62459","slug":"basis-for-recommendation-52f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4046e5fd-5397-4053-9ceb-9fd2cdc58353 --><h4>Basis for recommendation</h4><!-- end field 4046e5fd-5397-4053-9ceb-9fd2cdc58353 -->","summary":null,"htmlStringContent":"<!-- begin item 52f5f91b-18c5-4e54-be86-66503d79ccf6 --><!-- begin field 2aef6d47-d5ae-4328-ab3f-3e6a03499bd5 --><p>The recommendations on management of end-stage multiple myeloma are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Care of dying adults in the last days of life</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">NICE, 2015b</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Bird, 2019</a>].</p><ul><li>Early referral to palliative care has been shown to improve end-of-life care leading to fewer emergency department attendances, admissions, and hospital deaths in the last 30 days of life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Bird, 2019</a>].</li><li>The recommendation on adjustment of drug dosage in renal impairment is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Bird, 2019</a>].</li></ul><!-- end field 2aef6d47-d5ae-4328-ab3f-3e6a03499bd5 --><!-- end item 52f5f91b-18c5-4e54-be86-66503d79ccf6 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}